Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
editas medicine
biotech
boston
boston blog main
boston top stories
crispr
gene editing
life sciences
national blog main
allergan
clinical trials
cynthia collins
san francisco blog main
abbvie
agios therapeutics
alzheimer's disease
base editing
bill gates
bio
branden moriarty
broad institute
cas13
crispr therapeutics
crispr-cas9
david liu
deals
dna
drugs
editor
editr
enzyme
feng zhang
google ventures
government
harvard university
health
initial public offering
intellia therapeutics
john evans
katrine bosley
What
editas
4
×
editing
gene
4
×
crispr
biotech
experimental
medicine
abbvie
allergan
alliance
beam
believe
blessing
bosley
built
cas
ceo
check
clinical
company’s
concerns
cusp
debut
depart
dispute
drop
drops
editor
exits
far
founders
genetic
gotten
harvard
hours
humans
ipo’s
jump
katrine
legally
Language
unset
Current search:
editas
×
gene
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
@techcrunch.com
8 years ago
Editas biotech stock drops by 26% over CRISPR patent dispute